Find trials
Search tips

A Study to Create a Registry for Users of Opsumit

Overview

About this study

The purpose of this registry is to characterize the safety profile (especially potentially serious risks to the liver) and describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Newly treated with Opsumit  initiated ≤ 30 days prior to enrollment visit
  • Signed consent form

 

Exclusion Criteria

  • Previous user of Opsumit who initiated therapy >30 days prior to enrollment
  • Enrolled in any ongoing clinical trials

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Hilary DuBrock, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20178000

Mayo Clinic Footer